Full Likelihood Analysis of Genetic Risk with Variable Age at Onset Disease-Combining Population-Based Registry Data and Demographic Information by Pitkäniemi, Janne et al.
Full Likelihood Analysis of Genetic Risk with Variable
Age at Onset Disease—Combining Population-Based
Registry Data and Demographic Information
Janne Pitka¨niemi1*, Sirkka-Liisa Varvio2, Jukka Corander2, Nella Lehti2, Jukka Partanen4,
Eva Tuomilehto-Wolf3, Jaakko Tuomilehto1, Andrew Thomas2, Elja Arjas2,3
1Department of Public Health, University of Helsinki, Helsinki, Finland, 2Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland, 3National
Public Health Institute, Department of Health Promotion and Chronic Diseases Prevention, Helsinki, Finland, 4 Finnish Red Cross Blood Service, Department of Tissue
Typing, Helsinki, Finland
Abstract
Background: In genetic studies of rare complex diseases it is common to ascertain familial data from population based
registries through all incident cases diagnosed during a pre-defined enrollment period. Such an ascertainment procedure is
typically taken into account in the statistical analysis of the familial data by constructing either a retrospective or
prospective likelihood expression, which conditions on the ascertainment event. Both of these approaches lead to a
substantial loss of valuable data.
Methodology and Findings: Here we consider instead the possibilities provided by a Bayesian approach to risk analysis,
which also incorporates the ascertainment procedure and reference information concerning the genetic composition of the
target population to the considered statistical model. Furthermore, the proposed Bayesian hierarchical survival model does
not require the considered genotype or haplotype effects be expressed as functions of corresponding allelic effects. Our
modeling strategy is illustrated by a risk analysis of type 1 diabetes mellitus (T1D) in the Finnish population-based on the
HLA-A, HLA-B and DRB1 human leucocyte antigen (HLA) information available for both ascertained sibships and a large
number of unrelated individuals from the Finnish bone marrow donor registry. The heterozygous genotype DR3/DR4 at the
DRB1 locus was associated with the lowest predictive probability of T1D free survival to the age of 15, the estimate being
0.936 (0.926; 0.945 95% credible interval) compared to the average population T1D free survival probability of 0.995.
Significance: The proposed statistical method can be modified to other population-based family data ascertained from a
disease registry provided that the ascertainment process is well documented, and that external information concerning the
sizes of birth cohorts and a suitable reference sample are available. We confirm the earlier findings from the same data
concerning the HLA-DR3/4 related risks for T1D, and also provide here estimated predictive probabilities of disease free
survival as a function of age.
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Introduction
Family data utilized in genetic association studies of rare
diseases are usually ascertained by initially recruiting individuals
with the phenotype of interest from some background population.
After this initial study phase, it is possible to gain information
about the relatives of the recruited subjects. Such an ascertainment
procedure is usually taken into account in the statistical analysis of
familial data by constructing either a retrospective or prospective
likelihood expression, which conditions on the ascertainment event
[1]. Complex ascertainment procedures often lead to inferential
difficulties; recently proposed computationally intensive methods
can however provide ways to resolve such issues [2].
In the statistical analysis of variable age at onset diseases, the
versatility of traditional survival analysis methods has been
frequently demonstrated in genetic linkage and association
studies [3–7]. Recent advances in modern non-parametric
Bayesian survival modeling have however mainly been utilized
outside the domain of genetic research [8–9]. To create a
likelihood-based framework for estimating disease risks associat-
ed with the genetic information and other possible factors
available, we use here an approach where a population based
ascertainment procedure is combined through a statistical model
with the demographic data describing also the non-ascertained
part of the target population.
Our framework is illustrated by a model of the T1D risks
associated with polymorphic markers located in the HLA region of
chromosome 6 in the Finnish population. Although our approach
is more generally applicable, the model framework is presented
directly in the T1D context in order to make it more easily
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accessible for readers with an interest in genetic epidemiology
rather than in statistical methodology per se. The family based
T1D data set was collected as a part of the DiMe study [10], and
has been previously analyzed by other statistical methods [11–12].
The additional reference data utilized in the present work are
taken from a large sample (,20,000 individuals) of unaffected
Finns at the Finnish Bone Marrow Donor Registry (BMDR), who
had been serotyped for the same HLA loci as the family members
included in the DiMe Study. These two sources of information are
further appended with the available demographic facts about the
population at risk during the ascertainment period. Since the
dominance effects of HLA-DRB1 are known to be highly genotype
dependent, we chose to model the effects of HLA-DRB1
genotypes, rather than alleles [13], as has been done in the
previous analyses using these same data. All genotype-associated
risks are here estimated jointly within a hierarchical Bayesian
hazard modeling framework. Similarly, in our risk model it is not
assumed that the considered haplotype effects could be expressed
as corresponding functions of allele effects.
In the next section we provide some details of the available data
sets, introduce a risk model for the genotype/haplotype effects on
age at the onset of the disease, and derive the corresponding
likelihood function and the joint posterior density of all model
parameters. Then the numerical results from the analysis are
presented. In the final part of the paper, we discuss some merits of
the proposed method for accounting for the effect of the
ascertainment, evaluate the empirical results, and suggest some
possibilities for future work in this area.
Materials and Methods
Data sources
We consider the situation in which ascertainment is based on all
incident cases in the target population during the enrollment
period (the recruitment window). This then leads to observed data
on sibships with a proband, and his/her siblings who have been at
risk for the disease under investigation. In our application, the
observed data consist of four parts:
1. Age at (possible) onset of T1D among all members of the
ascertained families, who have been at risk during the follow-up
period. Here, only diagnoses reported before the age of 15
years are considered. A total of 768 families are included in the
recruited group.
2. HLA genotypes of the members of the ascertained nuclear
families.
3. The numbers of the individuals in the background population
at risk, comprising of the individuals who were alive during the
calendar period included in the recruitment window (y = 1987,
1988, 1989) and belonging to the age groups a= 0,…,14.
4. The HLA genotypes from approximately 20,000 unrelated,
healthy Finns. This population reference group thus corre-
sponds to the control individuals utilized in case-control
association studies.
The Lexis diagram displayed in Figure 1 illustrates the
ascertainment procedure for sibships and the data needed to
Figure 1. Lexis diagram of the population-based ascertainment of Finnish sibships with Type 1 diabetes. An example of an ascertained
sibship included in the population-based disease registry data, because an individual (proband) younger than 15 years who was diagnosed with T1D
during the recruitment period 1.1.1987–30.4.1989.
doi:10.1371/journal.pone.0006836.g001
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construct the likelihood for an absolute risk model. Let i= 1, …, I
index all the ascertained families, j= 1, …, Ji indexing the
individuals (siblings including the proband) in the ith family, and
dij being the indicator for right censoring of the follow-up (dij = 1 if
individual j in family i was diagnosed with T1D in the recruitment
window, and dij = 0 if right censored. Let Xij represent the age at
onset or the age at a censoring event. Further, for the siblings in
the family data, let Gijl~ Gijlm,Gijlf
n o
be the phase unknown
marker alleles over the set of loci of interest, where l= 1,…, NL,
and let Gijlp be phased alleles where p =m, f index the parents of
the ith family. The alleles received from the mother (m) and the
father ( f ) are indexed accordingly, and an analogous indexing is
later used for haplotypes as well. Parental genotypes are denoted
by GMijlp,G
F
ijlp. In order to actually model risks associated with
haplotypes, it is assumed that the haplotype phases have been
resolved computationally prior to the risk analysis. The HLA-A,
HLA-B and HLA-DRB1 loci are included in the current data of
the HLA region. The observed data of the ascertained sibships
(Parts 1 and 2) are thus collectively represented by the set
Xij ,dij ,Gijlp,G
M
ijlp,G
F
ijlp; i~1,:::,768,
n
j~1,:::,Ji, l~A,B,DRB1, p~m,f g
The T1D families were collected from the nationwide T1D
registry in Finland, ascertained within the DiMe study [10]
through a child under the age of 15 years and diagnosed between
January 1, 1987 and April 30, 1989. The Childhood Diabetes in
Finland (DiMe) study was a large population-based genetic-
epidemiologic family study of T1D. Nationwide, all T1D cases
under the age of 15 in Finland were diagnosed. The cut-off age
was chosen purely for practical reasons. Newly diagnosed children
under the age of 15 years with T1D were hospitalized in the
pediatric wards in Finland and therefore were easier to recruit
than older subjects with T1D. T1D status was checked against the
data of the National Drug Registry. Of the 801 cases in the study
800 had also been registered in the Drug Registry and one person
died soon after the diagnosis. The participation rate in the study
was approximately 95%. Parents and siblings of the 801 probands
were also asked to participate. Extensive questionnaires were filled
in and blood samples were taken from participants. Probands,
their parents and siblings were HLA genotyped at A, B, C and DR
loci using conventional serology (768 families). Details of study
procedures, especially data collection, are described elsewhere
[10]. For the ascertained families we constructed a follow-up of
T1D until 31.12.2001, by updating the T1D status and the date of
diagnosis from the National Hospital Discharge Registry (Part 1).
An individual was thus considered censored if he/she reached the
age of 15 without having been diagnosed to have T1D, or was less
than 15 years old and was not yet diagnosed on 31.12.2001.
In summary, we have for the comprehensive statistical analysis
of HLA-A, HLA-B, and DRB1 loci, a total of 768 ascertained
families comprising 1,944 probands or siblings. HLA genotypes
were available from 1,342 probands or siblings (684 families, see
Table S1). The DiMe study protocol has been described in detail
elsewhere [14] and it has been approved by the ethics committees
of the participating hospitals. Informed consent was obtained from
the families taking part in the study. The HLA genotyping (Part 2)
of these families was done in the National Public Health Institute
Laboratory using classical serology. Haplotypes within the sibships
in the ascertained family data were established using the
SimWalk2 software [15], based on the available information
about the parental HLA genotypes.
In order to include demographic information in the likelihood
(Part 3), we assume that the sizes of the birth cohorts are known
for the relevant time period. Here they are denoted by
Nb; b~1972, 1973, . . . , 1989f g (see Figure 1). Let the starting
and end points of the recruitment window be denoted by c0 and c1,
respectively, and let w be the maximum age at which a subject
may be ascertained (here less than 15 years). As the ascertainment
is population-based, with a negligible magnitude of missing cases
during the recruitment period, it is possible to incorporate in the
risk model information about all individuals who were born during
a certain calendar time interval and who had passed the
recruitment window without being ascertained. This corresponds
to all subjects born in the population between the calendar time
points c0-w and c1. We divide subjects born in the general
population such that they could have become probands but did
not, into three sets according to the recruitment window as shown
in Fig. 1. Subjects born during the time interval (c0-w, c1-w) are in
the sequel indexed by k1, respectively subjects born during (c1-w, c0)
are in the sequel indexed by k2, and finally, subjects born during
the recruitment period (c0, c1) are indexed by k3. The demographic
information allows us to treat these individuals systematically in
the risk model via the known sizes of the birth cohorts.
The genetic information concerning HLA for the demo-
graphic data (Nb) is in our model formulation inferred from the
genotypic data in the population reference sample (Part 4).
From the BMDR we obtained comparable genotypes for HLA-
A, HLA-B and DRB1 loci for 19,386 unrelated individuals.
The BMDR database includes healthy individuals who had
agreed to volunteer for possible bone marrow donation. The
Finnish BMDR registry is owned by the Finnish Red Cross
Blood Service and it is not a public database. The primary
purpose of this registry is to search for potential bone marrow
donors for transplantations. All individuals who have joined
the BMDR registry have given their written consent for
anonymous registry based research. Anybody full filling the
health criteria (roughly equivalent to those required for blood
donation) and willing to donate stem cells (or ‘‘bone marrow’’)
for stem cell transplantation can join the registry. The registry
does not accept joining that is based on, or motivated, by
‘targeted’ donation to e.g. relative or friend only, but the
registree must be willing to donate to any patient. The bone
marrow transplantations between related individuals are
handled separately from the BMDR. Hence, we had no reason
to believe that members of the BMDR are more related to each
other than general population. From subjects who had given
written consent, about 10 mL of peripheral blood was drawn
for standard HLA typing. HLA typing included the standard
serological HLA-A and -B typings and either serological (early
samples) or DNA-based DRB1 typing. Genotype consistent
HLA haplotypes for the BMDR data were constructed with the
PHASE software [16]. In order to be able to compare HLA
genotypes/haplotypes between different data sources or typing
methods, all HLA types were converted to pooled alleles (see
supplementary material), if necessary, to the serological main
specificities according to the official HLA nomenclature [17].
Let GCrl~ G
C
rlm,G
C
rlf
n o
; r~1 , . . . , 19836 , l~A, B, DRB1
n o
be the set of genotypes for the unrelated individuals in the
BMDR database, using a notation analogous to the familial
data. These reference individuals are known not to have
acquired T1D before age w. The genotype and haplotype
frequencies for this reference population are collectively
denoted by qCg~ q
C
g1, . . . ,q
C
gng
 
and qCh~ q
C
h1, . . . ,q
C
hnh
 
,
respectively.
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Modeling of genetic risks and of the family-based
ascertainment procedure
Hazard model. Establishing associations between T1D and
the classical highly polymorphic linked marker loci within the HLA
region is a challenging task from a statistical perspective, due to the
large number of parameters in the risk model formulation that need
to be estimated. The first part of the risk model specifies the hazard
of acquiring T1D for individual j in family i, as a function of age a.
For both the genotype and haplotype effect models we use a discrete
time hazard model and index age by a= 0,…,14 corresponding to
the age intervals 0,1½ Þ, 1,2½ Þ, . . . 14,15½ Þ. For the genotype effect
model, the hazard is assumed to be of form
lija~la exp b Gijlm,Gijlf
   ð1Þ
Here la is a baseline hazard in the population and b[Gijlm,Gijlf]
are the genotype effects representing the molecular marker
information at l= HLA-A, HLA-B, HLA-DRB1, each locus being
considered and analyzed separately. For the analysis of the effects
of the HLA- A, -B and DRB1 haplotypes, we use the
corresponding ‘‘marginal’’ model in which the effect is always
randomly attributed to one of the two haplotypes Hijm,Hijf
n o
of a
considered individual. More precisely, we consider effects of the
form b [Hijp], p =m, f, where the index p, or phase, is treated as
missing data in the corresponding Bayesian model, assigning the
prior probability of 0.5 to both m and f.
Likelihood expression
An assumption of the conditional independence of individual
disease onset times, conditionally given the model parameters,
leads to the following likelihood expression for the combined set of
data:
P
I
i~1
P
Ji
j~1
P
Xij{1
a~0
1{lija
  
l
dij
ijXij
1{lijXij
 1{dij
| P
k1 :bk1 [ c0-w,c1-wð Þ
1- Sk1 c0{bk1 ; bð Þ{Sk1 15; bð Þ½ ð Þ
| P
k2 :bk2 [ c1-w,c0ð Þ
1- Sk2 c0{bk2 ; bð Þ{Sk2 c1{bk2 ; bð Þ½ ð Þ
| P
k3 :bk3 [ c0,c1ð Þ
Sk3 c1{bk3 ; bð Þ
ð2Þ
The first factor in this likelihood expression is the direct
contribution of the DiMe family data, with i= 1, …, I indexing all
the ascertained families, j= 1, …, Ji indexing the individuals
(siblings including the proband) in the ith family, and dij being the
indicator for right censoring of the follow-up (dij = 1 if individual j
in family i was diagnosed with T1D in the recruitment window,
and dij = 0 if right censored, cf. Figure 1).
The next three factors in (2) are the contributions of the
individuals, indexed here with k1, k2 and k3, in the background
population. These indexes represent the non-ascertained individu-
als, who could have been diagnosed with T1D in the ‘‘ascertainment
window’’, but who were in fact not ascertained to the DiMe sample.
These non-ascertained individuals are considered individually in the
‘‘full likelihood’’ function (2). Let c0{bk1 be the age of individual k1,
who was born at bk1 , at the beginning of the recruitment period.
Similarly c0{bk2 and c1{bk2 are the ages of an individual k2 born
at bk2at the beginning and at the end of the recruitment interval,
and c1{bk3 is the age of an individual born at bk3 at the end of the
recruitment interval. Then 1{ Sk1 c0{bk1 ; bð Þ{Sk1 15; bð Þ½ ,
1{ Sk2 c0{bk2 ; bð Þ{Sk2 c1{bk2 ; bð Þ½  and Sk3 c1{bk3 ; bð Þ are
the corresponding probabilities of not being diagnosed with T1D
in that interval, expressed here as a function of the parameters b of
the hazard model (1).
Note that since the hazard model (1) also contains in its
arguments the genotype/haplotype of the considered individual,
which is unknown for individuals of types k1, k2 and k3, they need
to be integrated away from the corresponding expressions of the
survival function. For the distribution of the genotypes/haplotypes
we made, for computational reasons, a shortcut and used their
empirical frequencies in the BMDR data base as the prior. (A
theoretically more satisfying solution could have been to postulate
the Dirichlet(1,…,1) prior for the frequencies and then update
their estimates by sampling, concurrently with the estimation of
other model parameters and using the BMDR genotypes/
haplotypes as data. However, in view of the size of this data base
we thought that doing so would not be worth the extra effort).
Note also that, with the genotype/haplotype information being
integrated away, all individuals of type k1 born at the same time
bk1are treated as exchangeable, and therefore the corresponding
product in (2) becomes a power, where the exponent is the number
of individuals (excluding those belonging to the DiMe families)
born at bk1 . These numbers are obtained directly from the
demographic data.
Bayesian inference
Next, we describe how the likelihood (2) can be calculated and
how the resulting parameter estimates are obtained. Applying the
Bayesian approach to statistical inference, the likelihood is
complemented with the joint prior distributions of all model
parameters and latent variables of interest. Here this is done by
following the principles of hierarchical Bayesian modeling and by
specifying the distributions appearing on the right hand side of the
following expression
p b,Gmiss
Xij ,dij ,Gijlp; i~1, . . . ,768, j~1, . . . ,Ji ,l~A,B,DRB1, p~m,f
	 

,
Nb; b~1972, . . . , 1989f g ,
GCrlp; r~1, . . . ,19863, l~A,B,DRB1, p~m,f
n o
1
CCCA

0
BBB@
! p bð Þ p Gmiss GM ,GF  p X , djb,G,GC ,Nb ,
ð3Þ
in the OpenBugs MCMC software [18], where Gmiss are the
missing HLA genotypes/haplotypes in the ascertained sibships.
The prior distributions used for the model parameters b and
missing HLA genotypes were specified as follows. The age specific
log baseline hazards were assigned independent Gaussian priors
according to log(la) with mean -8 and precision (reciprocal of
variance) equal to 0.000001, where a = 0,…,14. The genotype/
haplotype effects were assigned independent truncated normal
(210,10) prior distributions with mean 0.0 and precision
0.000001. This is, effectively, the uniform distribution over the
interval (210, 10). Particularly when noting that b is in the hazard
model (1) in the exponent, this interval can be said to cover more
than adequately all plausible values of genotype or haplotype
effect.
The prior of the missing HLA genotypes Gmissð Þ in the family-
based data was treated according to available parental HLA
genotype information. Two distinct situations of missing HLA
genotypes can be identified among the ascertained sibships:
1) Both parents were genotyped, but not all children. Here
Mendel’s law of segregation was utilized to assign the two
parental alleles with equal probabilities, and then applying
Population-Based Ascertainment
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the method of data augmentation, as a part of the resulting
Bayesian computation.
2) Genotype information was missing from at least one parent
and no children were genotyped. Here, the logically
consistent way to treat the missing data problem would
involve using Bayes’ formula, with the haplotype frequencies
of the parents of the ascertained families as a ‘‘prior’’
probability distribution, while Mendel’s law defines the
likelihood. However, in the 40 ascertained families, where
parental HLA information was missing and some sibs were
genotyped, the inference was implemented as in 1), despite
the fact that some inconsistent genotypes may then be
obtained. This was done in order to avoid a further increase
in the computational burden of implementing the already
complex model when using OpenBugs software [18].
In the final implementation we first obtained the posterior mean
of the baseline hazard for T1D using a model without the HLA
effects. In the reported analyses of the HLA genotype and
haplotype effects, the baseline hazard was held fixed at this
posterior mean. This strategy was chosen in view of the fact that
the Finnish birth cohorts, approximately 60,000 each and
effectively forming the risk sets of our population based analysis,
are so large that the joint estimation of the baseline hazards with
the other model parameters would have hardly led to numerically
different estimates. The reported analyses are based on 5,000
iterations (5,000 burn-in), and the estimates of genotype effects
passed the convergence diagnostics criteria of Geweke [19] (R-
program package CODA). In order to describe the age
dependency in the HLA genotypes, we calculated the genotype
and haplotype specific predictive disease free survival functions
and its’ 95% credible intervals. It is the expectation of disease free
survival function, with respect to the joint posterior distribution of
all model parameters [20].
Results
Given the complexity of the genetic information, only concise
summaries of the results can be reported here. The numbers and
percentages of particular genotype/haplotype carriers with T1D,
as well as the corresponding healthy carriers in the ascertained
sibships and in the BMDR sample, together with the associated
predictive probabilities of T1D free survival, are given in Table 1.
Predictive probabilities of T1D free survival are shown in Figure 2
for some high risk HLA DRB1 genotypes and in Figure 3 for a set
of selected haplotypes.
As could be expected from many earlier studies, the
heterozygous genotype DR3/DR4 at the DRB1 locus was
associated with the lowest predictive probability of the T1D free
survival to the age of 15, the estimate being 0.936 (0.926; 0.945
95% credible interval), compared to the average population T1D
free survival probability of 0.995. The effect of DR4 homozygote
was also strong with associated probability of 0.962 (0.954; 0.969)
for T1D free survival. Carriers of DR1/DR2, a common genotype
in the reference population and of DR2/DR6, had virtually no
risk of T1DM before the age of 15, with a predictive probability
for T1D free survival very close to 1. All DRB1 genotypes
associated with a lower predictive probability of T1D free survival
than the population average contained the DR4 allele: DR3/DR4,
DR4/DR4 DR4/DR8, DR4/DR6, DR4/DR7, DR1/DR4, and
DR4/DR5.
At the HLA B locus, the genotype associated with the smallest
predictive probability of T1D free survival to the age of 15 was
B8/B22, for which the estimate was 0.962 (0.944; 0.976). Two
common B-locus genotypes, viz. B7/B35 and B12/B35, were
observed to have only a few carriers among the diagnosed cases
while each had more than 50 carriers in the reference sample and
had therefore a predictive probability for T1D free survival that
was very close to one. Of the considered HLA-A locus genotypes,
A1/A9 genotype conferred the highest T1D risk, with a predictive
probability of 0.998 (0.994; 1.000) for T1D free survival among all
HLA-A genotypes.
Finally, the analysis of haplotypes revealed several haplotypes
with non-neutral association with T1D, in the sense of having a
smaller predictive probability of T1D free survival to 15 years than
the population average. Of these, the three highest ranked
haplotypes, with more than 50 carriers in the reference sample,
were A2/B22/DR4 0.935 (0.918; 0.950), A2/B18/DR4 0.944
(0.901; 0.976) and A2/B15/DR4 0.943 (0.924; 0.959). Notably, all
but one among the top ten ranked haplotypes contained the HLA
DR4 allele.
Discussion
To our knowledge, genetic risk estimation from an ascertained
familial data for a variable age at onset disease has not been earlier
approached by a full likelihood, or Bayesian, method utilizing
demographic information. The problem of non-random ascer-
tainment has been usually approached by formulating a
conditional likelihood [21], which leads to the removal of some
individuals from the study material in order to avoid an outcome-
based ascertainment bias. In our approach such an exclusion
procedure is not needed and all ascertained familial data can be
used in the statistical analysis. The basic modeling assumption in
the present work is that the putative effects associated with the
observed molecular information modulate a common age-
dependent baseline hazard in a multiplicative fashion. Also, we
do not assume any particular functional form for the genotype or
haplotype effects, i.e., they are not assumed to be decomposable
into some corresponding allelic effects.
Direct comparisons of our results to previously published studies
concerning genotype/haplotype risks of HLA for T1D are
difficult, as our analysis is restricted to the serotype level due to
restrictions in the available data, whereas the risk estimates are
currently provided at a finer molecular resolution. Thus our
analysis of the T1D data should be viewed primarily as an
example illustrating the potential of the likelihood based approach.
The T1D data from the DiMe Study have been analyzed earlier
for the allelic, genotypic, and/or haplotypic relative risks, by
estimating separately the risk associated with each haplotype by
the ratio of frequencies of transmitted and non-transmitted
haplotypes [22,14], or by assuming multiplicative genotype and
haplotype dominance effects on TIDM relative risk [11–12]. The
major difference in our model compared to that of Thomas et al.
[12] is that we do not assume multiplicative dominance effects
between alleles at the same locus but rather model directly the
effects of genotypes. Despite this difference, we observe a similar
ranking of the locus and haplotype effects as in Thomas’s et al.,
with the DRB1 locus genotypes having the largest effect. Of all
genotypes and common haplotypes considered, the DR3/DR4
genotype was associated with the smallest probability of surviving
T1D free to the age of 15. The association between T1D and
HLA-DRB1 DR3/DR4 genotypes has been known for decades,
and the current population-based analysis supports this conclu-
sion. Note, however, that the estimated cumulative risk of 4.3%
associated with the DR3/DR4 heterozygote is much lower than
what has been reported in UK families (approximately 14.4%,
pooling DR3/DR4 subtypes) [23]. The failure of Pitka¨niemi et al.
Population-Based Ascertainment
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[24], when analyzing the same data, to identify anything else than
DR3 and DR4 alleles to be statistically significant contributors to
the risk is likely due to the ascertainment correction and the
consequent substantial loss of data. Considering haplotypes, we
found the same T1D associated haplotype A2/B22/DR4
(probability 0.959 of being T1D free to the age of 15) that has
been identified earlier both by Tuomilehto-Wolf et al. [14] and by
Thomas et al. [12], along with several more rare haplotypes with
an even higher risk of T1D.
While gaining statistical power by incorporating the ascertain-
ment process in the full likelihood, this study has some clear
limitations. In terms of the analysis of T1D risk associated with
HLA genotypes, genotypes DRB1*04 subtypes were not available.
This is a limitation, because it is known to be the high risk
genotype and would have made the analysis population based
registry data more interesting. In the present study, we have not
included any non-genetic measured covariate effects in the model,
since there were no measurements available for the large reference
data. However, in the presence of such information, the hazard
model can be easily modified also to take such information into
account. In principle, the risk contribution of each allele at a
particular locus could be mediated through a latent partition of the
haplotypes into several risk categories, in a similar manner as was
done by Seaman et al. [25]. However, with the current computing
power available in single workstations, such an approach would be
very tedious to pursue in a numerically stable manner. Also, it
would be possible to refine our approach further by modeling the
familial structures in the general population, and then carry out
the corresponding MCMC simulations. This would increase the
computational burden significantly, and very likely lead to no real
Table 1. Numbers of genotype/haplotype carriers and predictive disease free survivals (95% credible intervals) of certain HLA-A, B
and DRB1 genotypes/haplotypes1.
HLA
Genotype/
Haplotype
# of
cases
% of
cases
# of healthy
carries in
ascertained
sibships
% of healthy
carries in the
ascertained
sibships
Number of
healthy carriers
in the BMDR
Predictive T1DM free
survival before age 5
(95% credible interval)
Predictive T1DM free
survival before age 10
(95% credible interval)
Predictive T1DM free
survival before age 15
(95% credible interval)
DRB1
3/4 173 23.44 42 6.84 481 0.984 (0.981;0.986) 0.958 (0.951;0.964) 0.936 (0.926;0.945)
4/4 88 11.92 42 6.84 417 0.990 (0.988;0.992) 0.975 (0.969;0.980) 0.962 (0.954;0.969)
4/8 71 9.62 50 8.14 561 0.995 (0.994;0.996) 0.987 (0.984;0.990) 0.980 (0.975;0.984)
…
3/3 8 1.08 6 0.98 231 0.999 (0.998;0.999) 0.996 (0.994;0.998) 0.994 (0.990;0.998)
…
1/2 2 0.27 15 2.44 1104 1.000 (1.000;1.000) 1.000 (1.000;1.000) 1.000 (0.999;1.000)
2/6 0 0 8 1.3 862 1.000 (1.000;1.000) 1.000 (1.000;1.000) 1.000 (1.000;1.000)
B
8/56 21 2.85 7 1.14 88 0.992 (0.988;0.995) 0.976 (0.964;0.985) 0.962 (0.944;0.976)
8/15 62 8.40 18 2.93 447 0.996 (0.994;0.997) 0.987 (0.983;0.990) 0.979 (0.974;0.984)
…
7/17 7 0.95 16 2.61 744 1.000 (1.000;1.000) 1.000 (0.999;1.000) 1.000 (0.998;1.000)
5/7 2 0.27 6 0.98 266 1.000 (0.999;1.000) 0.999 (0.998;1.000) 0.999 (0.997;1.000)
A
1/9 32 4.34 20 3.26 314 1.000 (0.999;1.000) 0.998 (0.996;1.000) 0.998 (0.994;1.000)
2/3 135 18.29 113 18.4 3292 0.999 (0.992;1.000) 0.998 (0.978;1.000) 0.996 (0.966;1.000)
A-B-DRB1
2 22 4 80 4.71 35 1.598 306 0.983 (0.979;0.987) 0.957 (0.946;0.967) 0.935 (0.918;0.950)
2 18 4 13 0.77 4 0.183 51 0.986 (0.974;0.994) 0.963 (0.934;0.984) 0.944 (0.901;0.976)
9 16 4 54 3.18 27 1.233 228 0.985 (0.980;0.990) 0.962 (0.950;0.973) 0.943 (0.924;0.959)
9 15 4 29 1.71 5 0.228 135 0.987 (0.981;0.992) 0.967 (0.952;0.980) 0.950 (0.927;0.970)
3 35 4 33 1.94 23 1.05 199 0.990 (0.986;0.994) 0.974 (0.963;0.983) 0.961 (0.944;0.975)
…
1 8 3 131 7.72 86 3.927 1867 0.998 (0.997;0.999) 0.995 (0.993;0.997) 0.992 (0.989;0.995)
…
3 35 1 60 3.53 70 3.196 3242 1.000 (1.000;1.000) 1.000(0.999;1.000) 1.000 (0.999;1.000)
3 7 2 5 0.29 32 1.461 1388 1.000 (1.000;1.000) 1.000 (1.000;1.000) 1.000 (1.000;1.000)
1Pooled allele labels based on the official HLA nomenclature (http://www.anthonynolan.org.uk/HIG/).
A9 = (9,23,24), A19 = (19,29,30,31,32,33), A28 = (28,68,69), B5 = (5,51,52),
B12 = (12,44,45), B14 = (14,64,65), B15 = (15,62,63,75), B16 = (16,38,39),
B17 = (17,57,58), B56 = (22,55,56), B21 = (21,41,50), B40 = (40,60,61),
DR2 = (2,15,16), DR3 = (3,17,18), DR5 = (5,11,12), DR6 = (6,13,14).
doi:10.1371/journal.pone.0006836.t001
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Figure 3. Predictive disease free survival of T1D for some high risk HLA A,B and DRB1 haplotypes.
doi:10.1371/journal.pone.0006836.g003
Figure 2. Predictive disease free survival of T1D for some high risk HLA DRB1 genotypes.
doi:10.1371/journal.pone.0006836.g002
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changes in the risk estimates. For the same reason, we did not
explicitly account in our modeling for the uncertainties in the
reconstruction of haplotypes from the BMDR data [26], although
such measures would have been available from the output of the
PHASE software.
We conclude that the likelihood-based Bayesian approach
considered here offers a flexible and coherent framework for
handling the uncertainty related to the risks associated with
various types of molecular and other factors. The same conclusion
has been reached recently within other areas of genetics [27], as
well as applied sciences in general.
Supporting Information
Table S1 The number of the ascertained subjects and families in
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